← Back to Search

Antibody-drug Conjugate

XMT-1592 for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Mersana Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed solid tumors of the types specified below, with incurable, locally advanced or metastatic disease that has failed standard therapy or for which no standard treatment option exists.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 6 weeks for up to 36 weeks
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a type of cancer that has spread or is too advanced to be treated with standard methods.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 6 weeks for up to 36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 6 weeks for up to 36 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose or recommended Phase 2 dose
Secondary outcome measures
Anti-drug antibody and neutralizing antibody
Antineoplastic effects of XMT-1592
Area under the concentration curve of the last measurable concentration of XMT-1592
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment1 Intervention
XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
Group II: Confirmation of DoseExperimental Treatment1 Intervention
New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose

Find a Location

Who is running the clinical trial?

Mersana TherapeuticsLead Sponsor
8 Previous Clinical Trials
1,257 Total Patients Enrolled
IQVIA BiotechIndustry Sponsor
18 Previous Clinical Trials
4,877 Total Patients Enrolled
Robert Burger, MDStudy DirectorMersana Therapeutics
4 Previous Clinical Trials
893 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I possibly qualify to participate in this research?

"Eligible participants for this study must have a non-small cell lung carcinoma (nsclc) and be between the ages of 18 and 95. So far, the study has recruited a total of 120 candidates."

Answered by AI

Does this experiment include geriatric participants?

"Eligibility criteria for this study include being between 18-95 years old."

Answered by AI

Is this research study currently looking for new participants?

"This clinical trial, as indicated on clinicaltrials.gov, is no longer actively recruiting patients. The study was originally posted on May 11th, 2020 but was most recently edited on August 29th, 2020. There are currently 2181 other studies recruiting patients."

Answered by AI

In how many distinct hospitals is this research project being conducted currently?

"Enrollment for this study is currently underway at 9 different locations, 8 of which are based in major cities such as San Antonio, Dallas and Detroit. If you are considering enrolling, it might be best to choose the nearest site to you in order to limit travel."

Answered by AI
~6 spots leftby Mar 2025